for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Blueprint Medicines Corp

BPMC.O

Latest Trade

75.15USD

Change

0.36(+0.48%)

Volume

621,488

Today's Range

72.43

 - 

75.53

52 Week Range

44.58

 - 

102.98

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
74.79
Open
74.13
Volume
621,488
3M AVG Volume
8.92
Today's High
75.53
Today's Low
72.43
52 Week High
102.98
52 Week Low
44.58
Shares Out (MIL)
49.12
Market Cap (MIL)
3,673.35
Forward P/E
-8.87
Dividend (Yield %)
--

Next Event

Q3 2019 Blueprint Medicines Corp Earnings Release

Latest Developments

More

Ipsen And Blueprint Medicines Sign Exclusive Global License Agreement For BLU-782

Blueprint Medicines Announces FDA Acceptance Of New Drug Application For Avapritinib For The Treatment Of PDGFRA Exon 18 Mutant Gist And Fourth-Line Gist

Blueprint Medicines Reports Second Quarter 2019 Financial Results

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Blueprint Medicines Corp

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease. Its drug candidate, BLU-285, targets KIT, including Exon 17 mutations, and targets PDGFRa, including the D842V mutation. These mutations activate receptor tyrosine kinases that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors (GIST), and systemic mastocytosis (SM). Its drug candidate BLU-554 targets FGFR4, a kinase that is activated in a defined subset of patients with hepatocellular carcinoma (HCC), the common type of liver cancer. It is engaged in developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is activated by mutations or translocations.

Industry

Biotechnology & Drugs

Contact Info

45 Sidney St

+1.617.3747580

http://www.blueprintmedicines.com/

Executive Leadership

Daniel S. Lynch

Chairman of the Board

Jeffrey W. Albers

President, Chief Executive Officer, Director

Michael Landsittel

Chief Financial Officer

Kathryn Haviland

Chief Operating Officer

Christopher K. Murray

Senior Vice President, Technical Operations

Key Stats

1.62 mean rating - 13 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-2.640

2017

-3.920

2018

-5.390

2019(E)

-8.431
Price To Earnings (TTM)
--
Price To Sales (TTM)
461.01
Price To Book (MRQ)
6.19
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-50.75
Return on Equity (TTM)
-46.20

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up